Citigroup
KROS icon

Citigroup’s Keros Therapeutics KROS Stock Holding History

Citigroup’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-14,100
Closed -$819K – 5898
2024
Q3 		$819K Buy
+14,100
New +$696K ﹤0.01% 3415

Other funds holding KROS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Citigroup's KROS Position: Q1 2026 in Review

Citigroup reduced its Keros Therapeutics (KROS) stake by 69% in Q1 2026, selling an estimated $75.7K and leaving 2,208 shares worth $24.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4769.

Citigroup first reported a position in KROS in Q2 2020 and has held it in 24 quarters since. The position peaked at $19.8M in Q4 2022. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Citigroup held 2,208 shares of Keros Therapeutics worth $24.4K as of Q1 2026.
  • Citigroup sold 4,901 Keros Therapeutics shares in Q1 2026, an estimated $75.7K.
  • Keros Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4769 holding.
  • Citigroup first reported a position in Keros Therapeutics in Q2 2020 and has held it in 24 quarters since.
  • Citigroup's Keros Therapeutics position peaked at $19.8M in Q4 2022.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.